{
  "ticker": "CMB",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975202",
  "id": "02975202",
  "pages": 9,
  "price_sensitive": true,
  "date": "20250731",
  "time": "1139",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250731/pdf/06mcn1vnrp7chs.pdf",
  "summary": "### **Material Information Summary (Quarterly Report - Appendix 4C)**  \n\n#### **Operational Highlights**  \n- **Elate Ocular\u00ae Phase 3 Trials**: Ethics approvals secured in Australia (26 Jun 2025) and US (9 May 2025); FDA CMC clearance confirmed post-quarter (11 Jul 2025).  \n- **Clinical Timeline**: First-patient-in on track for Q4 CY 2025; top-line data expected Q4 CY 2026.  \n\n#### **Financial Highlights**  \n- **Net Operating Cash Outflow**: **A$1.102m** (70% R&D spend).  \n- **Closing Cash Balance**: **A$0.166m** (30 Jun 2025).  \n- **Post-Quarter Funding**: Placement of **A$2.12m** (30 Jul 2025) and expected R&D tax refund (**~A$0.9m** in Q4 CY 2025).  \n- **Liquidity Outlook**: Funding secured for ~12 months via placement, tax refund, and ongoing strategic discussions (equity/non-dilutive options).  \n\n#### **Key Upcoming Milestones**  \n- **Q3 2025**: CRO contract execution, site activation.  \n- **Q4 2025**: First-patient-in, tax refund receipt.  \n- **Q4 2026**: Phase 3 top-line data.  \n\n*No other material information identified.*",
  "usage": {
    "prompt_tokens": 5028,
    "completion_tokens": 302,
    "total_tokens": 5330,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-31T01:50:49.127768"
}